They're the first. Everything that happens will shape whether this becomes safe.
At the edge of what it means to be human, Elon Musk's Neuralink has begun recruiting paralysis patients for the first regulated human trial of a brain-computer interface — a technology that would allow thought alone to move a cursor, type a word, or command a machine. The company arrived here after five years of development, a failed FDA bid, contested animal trials, and repeated missed timelines, yet it now holds the clearance to implant a chip into living human brains and listen to what the mind intends. What begins as a medical intervention for those with quadriplegia or ALS carries within it a much older and stranger question: where does the self end and the machine begin.
- Neuralink has opened its patient registry for the PRIME trial, inviting people with severe paralysis to become the first humans to carry its brain implant — a chip surgically placed in the region of the brain that governs movement intention.
- The road here was neither clean nor fast: the FDA initially rejected Neuralink's application over fears that implant components could migrate through brain tissue and cause damage upon removal, forcing the company back to the drawing board.
- Animal testing during development left a troubling record — a monkey died during Pong experiments, employees described a culture of rushed timelines, and federal investigators were reported to be examining the company's practices.
- Backed by $280 million in fresh funding and regulatory clearance in hand, Neuralink is pressing forward, but participants face six years of monitoring and long-term safety outcomes that no one yet fully understands.
- The FDA has signaled that consumer approval remains a distant and uncertain horizon, meaning the answers this trial seeks will take years to surface — and the stakes, written in neural tissue, could not be more personal.
Elon Musk's Neuralink opened its patient registry this week for the first human clinical trial of its brain implant technology. The study, called PRIME, will enroll people with quadriplegia from spinal cord injury or ALS, offering them the possibility of controlling a computer cursor or keyboard through thought alone. A robot-assisted surgeon would place a chip into the brain region responsible for movement intention; the device then records neural signals and translates them into digital commands. Participants commit to six years of involvement — eighteen months of intensive visits followed by five years of monitoring.
The milestone comes after a path far longer than Musk's public optimism implied. He predicted human trials at least four times beginning in 2019, yet the company didn't formally approach the FDA until 2022, and that first application was rejected. Regulators worried that implant components might migrate within the brain and that tissue could be damaged during device removal. Neuralink revised its approach and eventually secured clearance, though the timeline slipped well past Musk's forecasts.
The company's animal testing program has never been far from controversy. A monkey died during experiments meant to teach it to play Pong, and Reuters reported that employees described a workplace culture defined by pressure to hit market milestones — with animal deaths and careless procedures as byproducts. Federal investigators were said to be examining the company's practices. Neuralink declined to address the allegations.
Musk's vision for the project draws from science fiction, particularly authors who imagined neural implants weaving human consciousness into digital networks. That speculative inheritance now sits inside a regulated medical trial, funded by $280 million raised through a round led by Peter Thiel's Founders Fund. Before any consumer product can emerge, additional FDA approval will be required — and the agency has been candid that no clear pathway yet exists. The long-term safety of permanent brain implants, over decades of electrical stimulation and biological change, remains genuinely unknown. Neuralink's trial will begin to answer those questions, but the answers will arrive slowly, written in the experience of the people who volunteer to go first.
Elon Musk's Neuralink announced this week that it would begin recruiting paralysis patients for the first human test of its brain implant technology. The company, which has spent five years pursuing the goal of wiring human brains directly to computers, received clearance from an independent review board and opened its patient registry on Tuesday. The trial, called PRIME—Precise Robotically Implanted Brain-Computer Interface—will eventually enroll people with quadriplegia from cervical spinal cord injury or ALS, offering them a chance to control a computer cursor or keyboard using only their thoughts.
The procedure itself is straightforward in concept but extraordinary in execution. A surgeon, guided by a robot, will place a chip into the region of the brain responsible for movement intention. Once installed, the implant records neural signals and transmits them to an application that translates thought into digital command. Participants will commit to six years of involvement: eighteen months of regular clinic and home visits, followed by five years of ongoing monitoring. The company is accepting applications through its website.
This milestone arrives after a longer and more complicated path than Musk's public statements suggested. He has forecast human trials at least four times since 2019, yet the company didn't formally approach the FDA until 2022. That initial bid failed. Regulators cited two specific concerns: the possibility that implant components could migrate to other brain regions, and the risk of tissue damage when devices are eventually removed. Musk responded by saying the company had submitted most of its paperwork and could begin human testing within six months—a prediction that proved optimistic by several months.
The company's animal testing program has shadowed its development from the start. In 2022, a monkey died during experiments designed to teach it to play Pong, the vintage video game. Reuters reported in December that employees described a workplace culture of rushing toward market milestones, with animal deaths and careless procedures resulting. The same reporting indicated that federal investigators were examining the company's practices. Neuralink declined to comment on these allegations when CNN asked.
Musk's inspiration for the project traces to science fiction. According to Walter Isaacson's recent biography, Musk drew from authors like Iain Banks, who imagined neural implants called "neural lace" that could connect human consciousness directly to computers. That vision—part transhumanism, part Silicon Valley ambition—has now moved from speculation into regulated medical testing.
Financially, the company appears well-positioned. In a fundraising round led by Founders Fund, a venture firm established by PayPal co-founder Peter Thiel, Neuralink raised $280 million. The company announced the funding with characteristic confidence on X, Musk's social media platform, calling the human trial opening "the next chapter" in its story.
Before these implants reach the general market, they will need to clear additional regulatory hurdles. The FDA published guidance on brain-computer interfaces in 2021, acknowledging that the field is advancing rapidly but offering no clear pathway to approval for consumer use. The agency's caution reflects genuine uncertainty: no one yet knows the long-term safety profile of permanent brain implants, or what happens to neural tissue over decades of electrical stimulation and device presence. Neuralink's human trial will begin to answer those questions, but the answers will take years to emerge.
Citações Notáveis
To grant people the ability to control a computer cursor or keyboard using their thoughts alone— Neuralink, describing the initial goal of the implant
We're extremely excited about this next chapter at Neuralink— Neuralink, on opening human trials
A Conversa do Hearth Outra perspectiva sobre a história
Why does this matter now? Neuralink has been talking about human trials for years.
Because they finally have regulatory permission. The FDA said no in 2022—they were worried about the implant breaking apart inside the brain. Neuralink addressed those concerns, and now they can actually put chips in people's heads.
And the people signing up—what are they getting into?
They're paralyzed. They can't move their limbs. If this works, they could control a computer just by thinking about moving a cursor. That's genuinely transformative for someone locked in their own body.
But there's a catch.
Several. The company has a history of animal deaths during testing. Employees have said they're moving too fast. And nobody knows what happens to your brain after ten, twenty, thirty years with a foreign object in it.
So the first human patients are essentially guinea pigs.
They're volunteers who understand the risks. But yes—they're the first. Everything that happens to them will shape whether this technology ever becomes safe enough for wider use.
What does Musk want from this?
He wants to prove the concept works. He's talked about neural lace since he read science fiction. But right now, he just needs to show that a paralyzed person can move a cursor with their mind.